Abbott Laboratories Ltd lowering its 2022 sales forecast due to its ongoing recall of Similac and other infant formulas won’t surprise anyone, but a rapid recovery of market share in the category might.
The firm on 20 April reported its worldwide nutrition sales, which include adult as well as infant products, during the first quarter dropped a reported 7% to $1
It said that excluding US sales of those products during the quarter and the prior-year-period, reported nutrition sales for